ArticleScientific reports2014
Epidermal growth factor receptor (EGFR) pathway genes and interstitial lung disease: an association study.
Article in Scientific reports, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- Meta-analysis ofInternational journal of immunopathology and pharmacologyPooled it
- A case report of idiopathic pulmonary fibrosis concurrent withTranslational cancer research · 2026Article
- Global disease burden of interstitial lung disease and pulmonary sarcoidosis, 1990-2021, and forecast analysis over the next decade.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2025Article
- An epigenome-wide study of DNA methylation profiles and lung function among American Indians in the Strong Heart Study.Clinical epigenetics · 2022Article
- EGFR Signaling in Lung Fibrosis.Cells · 2022Review
- Controlled human exposures to diesel exhaust: a human epigenome-wide experiment of target bronchial epithelial cells.Environmental epigenetics · 2021Article
- Interstitial pneumonia suspected during regorafenib administration and exacerbated by subsequent therapy with lenvatinib for unresectable hepatocellular carcinoma.Clinical journal of gastroenterology · 2019Article
- Prognosticating Outcomes in Interstitial Lung Disease by Mediastinal Lymph Node Assessment. An Observational Cohort Study with Independent Validation.American journal of respiratory and critical care medicine · 2019Observational
- The Association between Epidermal Growth Factor Receptor (Biomolecules · 2018Article
- Type 2 macrophages and Th2 CD4+ cells in interstitial lung diseases (ILDs): an overview.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2018Review
- Antibody-nanoparticle conjugates to enhance the sensitivity of ELISA-based detection methods.PloS one · 2017Article
- Erlotinib Induced Fatal Interstitial Lung Disease in a Patient with Metastatic Non-Small Cell Lung Cancer: Case Report and Review of Literature.Rare tumors · 2016Article
- EGFR and SYNE2 are associated with p21 expression and SYNE2 variants predict post-operative clinical outcomes in HBV-related hepatocellular carcinoma.Scientific reports · 2016Article
- Systematical analyses of variants in CTCF-binding sites identified a novel lung cancer susceptibility locus among Chinese population.Scientific reports · 2015Article
- Unexpected responses to EGFR inhibition in NSCLC.Respiratory medicine case reports · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
The etiology and pathogenesis of idiopathic interstitial lung disease (ILD) remain incompletely understood. Genetic susceptibility to ILD has been demonstrated in previous studies. It is well known that EGFR inhibitors can induce ILD in human lung cancer patient with ethnic differences, which prompted us to hypothesize that genetic variation in EGFR pathway genes confer susceptibility to ILD. We aimed in this study to investigate whether functional polymorphisms of EGFR and its ligands genes (EGF and TGFA) were associated with ILD. Three EGFR [-216G/T (rs712830), -191A/C (rs712829), 497R > K(A/G) (rs2227983)], one EGF [61A/G, (rs4444903)] and one TGFA (rs3821262C/T) polymorphisms previously demonstrated to alter gene functions were genotyped in 229 sporadic idiopathic ILD patients and 693 normal healthy individuals. Allelic and genotypic association tests between these polymorphisms and ILD were performed. The EGF 61A/G polymorphism was significantly associated with elevated risk of ILD, with the frequency of G allele significantly increased in the ILD patient population (OR = 1.33, 95%CI = 1.07-1.66, P = 0.0099). None of the other polymorphisms were associated with risk of ILD. Our study suggested that the EGF 61A/G polymorphism may be associated with sporadic ILD. While a false positive finding cannot be excluded, independent studies are warranted to further validate this result.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.